Financials data is unavailable for this security.
View more
Year on year NovaBay Pharmaceuticals Inc had relatively flat revenues (14.40m to 14.73m), though the company grew net income from a loss of 10.61m to a smaller loss of 9.64m. A reduction in the selling, general and administrative costs as a percentage of sales from 106.13% to 87.12% was a component in the net income growth despite flat revenues.
Gross margin | 58.55% |
---|---|
Net profit margin | -87.67% |
Operating margin | -66.51% |
Return on assets | -105.75% |
---|---|
Return on equity | -549.55% |
Return on investment | -205.52% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at NovaBay Pharmaceuticals Inc fell by 2.24m. Cash Flow from Financing totalled 1.91m or 12.97% of revenues. In addition the company used 4.13m for operations while cash used for investing totalled 19.00k.
Cash flow per share | -28.94 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.4577 |
---|---|
Tangible book value per share | -0.4577 |
More ▼
Balance sheet in USDView more
Current ratio | 0.6241 |
---|---|
Quick ratio | 0.4302 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 8.81 |
More ▼